On Dec. 19, Milton M. Morris, Ph.D., senior vice president, research & development, resigned from the company due to personal reasons, according to a recent release.
The resignation is effective immediately, but in order to ensure a seamless transition, he will assist in shifting his responsibilities to other members of the company's R&D team. In addition, Morris has agreed to be available to provide consulting services for at least the next six months as the company continues to evaluate partnership opportunities for the chronic heart failure indication for the company's primary technology.
"I'd like to thank Milton for his important contributions to building our product development pipeline. He has helped establish a high-performance R&D team that will continue to deliver innovative technological solutions for our patients for years to come," commented Dan Moore, Cyberonics' president and CEO. "Given the high-quality senior R&D leaders currently in place at Cyberonics, we don't anticipate initiating a search for Milton's replacement at this time."
Cyberonics' core expertise is neuromodulation. The company developed and markets the VNS Therapy System, which is U.S. Food and Drug Administration-approved for the treatment of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses an implanted medical device that delivers pulsed electrical signals to the vagus nerve.